biotechnology company developing prophylactic therapeutics for bleeding and thrombotic disorders
Hemab Therapeutics has raised €127M across 1 funding round from 9 investors, most recently a Series B round in Feb 2023. Based in Copenhagen, Denmark; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-02-21 | Series B | €127M |
| Access Biotechnology,Avoro Ventures,Deep Track Capital,HealthCap,Invus,Maj Invest Equity+3 more |
| View deal → |
